Revvity to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference to provide an update on the Company and its strategic priorities.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.